Loncastuximab Tesirine Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Loncastuximab tesirine, also known as ADCT-402, an investigational antibody-drug conjugate being developed by ADC Therapeutics, showed signs of clinical...
Ultrafiltration and Diafiltration in the Clearance of Solvents and Small Molecule Impurities in ADC...
In a new article, published in the October 6, 2019 edition of Biotechnology Progress, Travis Gates, Yaqi Fara Lyu,...
Highlights in Development: September 2019
In September 2019, a number of articles discussing antibody-drug conjugates were published in a variety of journals. Here is...
ADC-based Conditioning with Platelet-directed HSC-based FVIII Gene Therapy Shows Promise in Hemophilia Treatment
Gene therapy for hemophilia, a condition in which the ability of the blood to clot is severely reduced, as...
Enabling Heterobifunctional, Dual “Click,” Antibody Modification via Microbial Transglutaminase
With 5 approved and commercially available antibody-drug conjugates, this class of therapeutics, combining the efficacy of small-molecule therapeutics with...
Identifying Regulators of Antibody–drug Conjugate Toxicity
Antibody–drug conjugates or ADCs selectively deliver a a cytotoxic payload to target cancer cells, making them important anti-cancer therapeutics....
Using a Hydrophilic Spacer to Reduce Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates
In the development of novel drug conjugates alternatives to monoclonal antibodies (mAbs) have started to emerge. While antibodies have...
Using Middle-Down Mass Spectrometry to Identify the Drug Conjugation Site of a Site-Specific Antibody-Drug-Conjugate
Antibody–drug conjugates are among the fastest growing classes of anti-cancer
therapeutics.With the 5 approved and commercially available agents, and nearly...
A Superglue for ADCs: Connecting the Cytsteine Residues of a Tumor-sensing Antibody to a...
The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU) hve developed an innovative technology designed to make...
Immunocapture-liquid Chromatography/Mass Spectrometry in Simultaneous Quantification of Total Antibody and ADC for XMT-1522 in...
XMT-1522, an investigational antibody-drug conjugate (ADC) being developed by Mersana Therapeutics and Takeda, represents the first Dolaflexin®-based, cleavable ADC...
